Dosing & Uses
Dosage Forms & Strengths
tablet (Piqray)
- 50mg
- 150mg
- 200mg
tablet (Vijoice)
- 50mg
- 125mg
- 200mg
Breast Cancer
Piqray only
Kinase inhibitor indicated in combination with fulvestrant for treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen
Alpelisib 300 mg PO qDay AND
Fulvestrant 500 mg IM on Days 1, 15, and 29, and once monthly thereafter
Continue treatment until disease progression or unacceptable toxicity occurs
Refer to the full prescribing information for fulvestrant
PIK3CA-Related Overgrowth Spectrum
Vijoice only
Indicated for patients aged ≥2 years with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy
250 mg PO qDay
Continue until disease progression or unacceptable toxicity
Dosage Modifications
Breast cancer dose reduction recommendations
- First-dose reduction: 250 mg PO qDay
- Second-dose reduction: 200 mg PO qDay
- Only 1 dose reduction permitted for pancreatitis
- If dose reduction <200 mg qDay required, discontinue treatment
PROS dose reduction recommendations
-
Adults
- First-dose reduction: 125 mg PO qDay
- Second-dose reduction: 50 mg PO qDay; discontinue if 50 mg/day not tolerated
Hyperglycemia
- Monitor by using only fasting glucose (FG) values (fasting plasma glucose [FPG] or fasting blood glucose)
- Initiate or adjust applicable antihyperglycemic medications, including metformin, SGLT2 inhibitors, or insulin sensitizers (eg, thiazolidinediones, dipeptidyl peptidase-4 inhibitors)
- Metformin dose was recommended in SOLAR-1 trial: Initiate metformin 500 mg PO qDay; may increase to 500 mg BID based on tolerability, followed by 500 mg with breakfast, and 1,000 mg with dinner, followed by further increase to 1,000 mg BID if needed
- May use insulin for 1-2 days until hyperglycemia resolves; may not be necessary in most drug-induced hyperglycemia, given short half-life of alpelisib and glucose levels normalizing after dose interruption
-
Grade 1
- FG >ULN to 160mg/dL OR >ULN to 8.9 mmol/L
- No dosage adjustment required
- Initiate/intensify antidiabetic therapy
-
Grade 2
- FG >160-250 mg/dL OR >8.9-13.9 mmol/L
- No dosage adjustment required
- Initiate/intensify antidiabetic treatment
- If FG not decreased to ≤160 mg/dL or 8.9 mmol/L within 21 days under appropriate antidiabetic treatment, reduce dose by 1 level and follow FG value specific recommendation
-
Grade 3
- FG >250-500 mg/dL OR >13.9-27.8 mmol/L
- Interrupt dose
- Initiate/intensify oral antidiabetic therapy and consider additional antidiabetic medications (eg, insulin) for 1-2 days until hyperglycemia improves
- Administer IV hydration and consider appropriate treatment (eg, intervention for electrolyte/ketoacidosis/hyperosmolar disturbances)
- If FG decreases to ≤160 mg/dL or 8.9 mmol/L within 3-5 days under appropriate antidiabetic treatment, resume at 1 lower dose level
- If FG not decreased to ≤160 mg/dL or 8.9 mmol/L within 3-5 days under appropriate antidiabetic treatment, consult with a physician specialist for treatment of hyperglycemia
- If FG not decreased to ≤160 mg/dL or 8.9 mmol/L within 21 days following appropriate antidiabetic treatment, permanently discontinue
-
Grade 4
- FG >500 mg/dL or ≤27.8 mmol/L
- Interrupt dose
- Initiate/intensify appropriate antidiabetic treatment
- Administer IV hydration and consider appropriate treatment (eg, intervention for electrolyte/ketoacidosis/hyperosmolar disturbances); recheck FG within 24 hr and as clinically indicated
- If FG decreases to ≤500 mg/dL or 27.8 mmol/L, follow recommendations for Grade 3 hyperglycemia
- If FG confirmed at >500 mg/dL or 27.8 mmol/L, permanently discontinue
Cutaneous adverse reactions
-
Confirmed etiology is severe cutaneous adverse reaction (SCAR)
- Permanently discontinue
- Do not reintroduce in patients who previously experienced SCAR during treatment
-
Grade 1
- <10% BSA with active skin toxicity
- No dosage adjustment required unless etiology determined to be SCAR (then permanently discontinue)
- Initiate topical corticosteroid treatment; consider adding oral antihistamine to manage symptoms
- Active rash not improved ≤28 days of appropriate treatment: Add a low dose systemic corticosteroid
-
Grade 2
- 10-30% BSA with active skin toxicity
- No dosage adjustment required unless etiology determined to be SCAR (then permanently discontinue)
- Initiate or intensify topical corticosteroid and oral antihistamine treatment
- Consider low-dose systemic corticosteroid treatment
- Rash improves to Grade ≤1 within 10 days: May discontinue systemic corticosteroid
-
Grade 3
- Severe rash not responsive to medical management; >30% BSA with active skin toxicity
- Interrupt dose and initiate or intensify topical/systemic corticosteroid and oral antihistamine treatment
- If etiology is not SCAR, once improved to Grade ≤1, resume at next lower dose level
-
Grade 4
- Severe bullous, blistering, or exfoliating skin conditions; any % BSA associated with extensive superinfection, with IV antibiotics indicated; life-threatening consequences
- Permanently discontinue
Diarrhea or colitis
- All grades: Initiate or intensify appropriate medical therapy and monitor as clinically indicated
- Grade 1: No dosage adjustment required
- Grade 2: Interrupt dose until recovery to Grade ≤1, then resume at same dose level
- Grade 2 and 3 colitis: Consider additional treatment (eg, enteric-acting and/or systemic steroids)
- Grade ≥2 recurs or Grade 3: Interrupt dose until recovery to Grade ≤1, then resume at next lower dose level
- Grade 4: Permanently discontinue
Pneumonitis
- Any grade: Interrupt dose if suspected
- Permanently discontinue if confirmed
Pancreatitis
- Grades 2 or 3: Interrupt until improvement to Grade <2; resume at next lower dose (only 1 dose reduction permitted); if recurs, permanently discontinue
- Grade 4: Permanently discontinue
Other toxicities
- Grades 1 or 2: No dosage adjustment required; initiate appropriate medical therapy and monitor as clinically indicated
- Grade 2 elevated total bilirubin: Interrupt dose until recovery to Grade ≤1 and resume at same dose if resolved in ≤14 days or resume at next lower dose level if resolved in >14 days
- Grade 3: Interrupt dose until recovery to Grade ≤1 and initiate/intensify appropriate therapy, then resume at the next lower dose level
- Grade 4: Permanently discontinue
Renal impairment
- Mild-to-moderate (CrCl 30 to <90 mL/min): No dosage adjustment required
- Severe (CrCl <30 mL/min): Pharmacokinetic data are unknown
Dosing Considerations
Patient selection (breast cancer)
- Select based on presence of ≥1 PIK3CA mutations in tumor tissue or plasma specimens
- If no mutation is detected in a plasma specimen, test tumor tissue
- Information on FDA-approved tests is available at: http://www.fda.gov/CompanionDiagnostics
Monitoring parameters
- Before initiation: FPG, HbA1c, and optimize blood glucose
- Verify pregnancy status in females of reproductive potential
-
During treatment
- FG: At least qWeek for first 2 weeks, then at least q4Weeks, and as clinically indicated
- HbA1c: Every 3 months and as clinically indicated
- Closely monitor FG for first few weeks in patients with risk factors for hyperglycemia, such as obesity (BMI ≥30), elevated FG, HbA1c ≥ULN, use of systemic corticosteroids, or age ≥75 yr
- Signs and symptoms of SCARs (eg, a prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, lymphadenopathy)
Dosage Forms & Strengths
tablet (Vijoice)
- 50mg
- 125mg
PIK3CA-Related Overgrowth Spectrum
Vijoice only
Indicated for patients aged ≥2 years with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy
<2 years: Safety and efficacy not established
2 to <6 years
- 50 mg PO qDay
- Continue until disease progression or unacceptable toxicity
6 to <18 years
- Initial: 50 mg PO qDay
- After 24 week: Consider increasing to 125 mg qDay for response optimization (clinical/radiological)
- Continue until disease progression or unacceptable toxicity
≥18 years
- Consider gradually increase up to 250 mg qDay
Dosage Modifications
PROS dose reduction recommendations
-
Pediatrics
- Dose prior to reduction is 125 mg qDay: Reduce to 50 mg PO qDay
- Dose prior to reduction is 50 mg qDay: Discontinue if 50 mg/day not tolerated
Hyperglycemia
- Monitor by using only fasting glucose (FG) values (fasting plasma glucose [FPG] or fasting blood glucose)
- Initiate or adjust applicable antihyperglycemic medications
- May use insulin for 1-2 days until hyperglycemia resolves; may not be necessary in most drug-induced hyperglycemia, given short half-life of alpelisib and glucose levels normalizing after dose interruption
-
Grade 1
- FG >ULN to 160mg/dL OR >ULN to 8.9 mmol/L
- No dosage adjustment required
- Initiate/intensify antidiabetic therapy
-
Grade 2
- FG >160-250 mg/dL OR >8.9-13.9 mmol/L
- No dosage adjustment required
- Initiate/intensify antidiabetic treatment
- If not decreased to ≤160 mg/dL or 8.9 mmol/L within 21 days under appropriate anti-hyperglycemic treatment, interrupt dosing until improvement to Grade ≤1, then resume at 50 mg and follow FG value specific recommendations
-
Grade 3
- FG >250-500 mg/dL OR >13.9-27.8 mmol/L
- Interrupt dose
- Initiate/intensify oral antidiabetic therapy and consider additional antidiabetic medications (eg, insulin) for 1-2 days until hyperglycemia improves
- Administer IV hydration and consider appropriate treatment (eg, intervention for electrolyte/ketoacidosis/hyperosmolar disturbances)
- If FG decreases to ≤160 mg/dL or 8.9 mmol/L within 3-5 days under appropriate antidiabetic treatment, resume at 50 mg
- If FG not decreased to ≤160 mg/dL or 8.9 mmol/L within 3-5 days under appropriate antidiabetic treatment, consult with a physician specialist for treatment of hyperglycemia if treatment should be resumed or permanently discontinued
- If FG not decreased to ≤160 mg/dL or 8.9 mmol/L within 21 days following appropriate antidiabetic treatment, permanently discontinue
- If hyperglycemia recurs at Grade ≥3, consider permanent discontinuation
-
Grade 4
- FG >500 mg/dL or ≤27.8 mmol/L
- Interrupt dose
- Initiate/intensify appropriate antidiabetic treatment
- Administer IV hydration and consider appropriate treatment (eg, intervention for electrolyte/ketoacidosis/hyperosmolar disturbances); recheck FG within 24 hr and as clinically indicated
- If FG decreases to ≤500 mg/dL or 27.8 mmol/L, follow recommendations for Grade 3 hyperglycemia
- If FG confirmed at >500 mg/dL or 27.8 mmol/L, permanently discontinue
Cutaneous adverse reactions
-
Confirmed etiology is severe cutaneous adverse reaction (SCAR)
- Permanently discontinue
- Do not reintroduce in patients who previously experienced SCAR during treatment
-
Grade 1
- <10% BSA with active skin toxicity
- No dosage adjustment required unless etiology determined to be SCAR (then permanently discontinue)
- Initiate topical corticosteroid treatment; consider adding oral antihistamine to manage symptoms
- Active rash not improved ≤28 days of appropriate treatment: Add a low dose systemic corticosteroid
-
Grade 2
- 10-30% BSA with active skin toxicity
- No dosage adjustment required unless etiology determined to be SCAR (then permanently discontinue)
- Initiate or intensify topical corticosteroid and oral antihistamine treatment
- Consider low-dose systemic corticosteroid treatment
- Rash improves to Grade ≤1 within 10 days: May discontinue systemic corticosteroid
-
Grade 3
- Severe rash not responsive to medical management; >30% BSA with active skin toxicity
- Interrupt dose and initiate or intensify topical/systemic corticosteroid and oral antihistamine treatment
- If etiology is not SCAR, once improved to Grade ≤1 may resume at 50 mg while continuing PO antihistamine treatment or permanently discontinue
- Permanently discontinue if patient was receiving antihistamines and antihistamine dose cannot be increased or if Grade >3 recurs
-
Grade 4
- Severe bullous, blistering, or exfoliating skin conditions; any % BSA associated with extensive superinfection, with IV antibiotics indicated; life-threatening consequences
- Permanently discontinue treatment
Diarrhea or colitis
- Consider consultation with physician experienced in treating gastrointestinal conditions
- All grades: Initiate or intensify appropriate medical therapy and monitor as clinically indicated
- Grade 1: No dosage adjustment required
- Grade 2: Interrupt dose until recovery to Grade ≤1, then resume at same dose level
- Grade ≥2 recurs: Interrupt dose until recovery to Grade ≤1, then resume at 50 mg
- Grade 2 and 3 colitis: Consider additional treatment (eg, enteric-acting and/or systemic steroids)
- Grade 3: Interrupt dose until recovery to Grade ≤1, either resume at 50 mg or permanently discontinue; consider permanent discontinuation if Grade >3 recurs
- Grade 4: Permanently discontinue
Pneumonitis
- Any grade: Interrupt dose if suspected
- Permanently discontinue if confirmed
Pancreatitis
- Grade 2: Interrupt until improvement to Grade <2; resume at 50 mg; if recurs, permanently discontinue
- Grades 3 or 4: Permanently discontinue
Other toxicities
- Grades 1 or 2: No dosage adjustment required; initiate appropriate medical therapy and monitor as clinically indicated
- Grade 2 elevated total bilirubin: Interrupt dose until recovery to Grade ≤1 and resume at same dose if resolved in ≤14 days or resume at 50 mg if resolved in >14 days
- Grade 3: Interrupt dose until recovery to Grade ≤1 and initiate/intensify appropriate therapy, resume at 50 mg or consider permanent discontinuation
- Grade 4: Permanently discontinue
Dosing Considerations
Monitoring parameters
- Before initiation: FPG, HbA1c, and optimize blood glucose
- Verify pregnancy status in females of reproductive potential
-
During treatment
- FG: At least qWeek for first 2 weeks, then at least q4Weeks, and as clinically indicated
- HbA1c: Every 3 months and as clinically indicated
- Closely monitor FG for first few weeks in patients with risk factors for hyperglycemia, such as obesity (BMI ≥30), elevated FG, HbA1c ≥ULN, use of systemic corticosteroids, or age ≥75 yr
- Signs and symptoms of SCARs (eg, a prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, lymphadenopathy)
Breast cancer: Patients aged ≥65 years had higher incidence of grade 3-4 hyperglycemia compared with patients aged <65 years
Patients aged ≥75 years (breast cancer) or ≥65 years (PIK3CA-related overgrowth spectrum [PROS]): Insufficient number of patients to assess differences in safety and efficacy
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (58)
- acalabrutinib
acalabrutinib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- apalutamide
apalutamide will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- atazanavir
atazanavir will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- bosentan
bosentan will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- butabarbital
butabarbital will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- butalbital
butalbital will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- carbamazepine
carbamazepine will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- cobicistat
cobicistat will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
cobicistat will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - cyclosporine
cyclosporine will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- dabrafenib
dabrafenib will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
dabrafenib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions. - darolutamide
darolutamide will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Darolutamide is a BCRP inhibitor. Avoid coadministration with BCRP inhibitors. If use is unavoidable, closely monitor for adverse reactions and consider dose reduction of BCRP substrate drug (refer BCRP substrate prescribing information).
- dipyridamole
dipyridamole will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- efavirenz
efavirenz will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- eltrombopag
eltrombopag will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- eluxadoline
eluxadoline will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- enzalutamide
enzalutamide will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- erdafitinib
alpelisib will increase the level or effect of erdafitinib by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. If coadministration of a strong CYP2C9 inhibitors is unavoidable, closely monitor adverse reactions and modify dose of erdafitinib accordingly. If strong CYP2C9 inhibitor is discontinued, consider increasing erdafitinib dose in the absence of any drug-related toxicities.
- etravirine
etravirine will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- fexinidazole
fexinidazole will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.
- fosphenytoin
fosphenytoin will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- gefitinib
gefitinib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- imatinib
imatinib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- ivosidenib
ivosidenib will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- ketoconazole
ketoconazole will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- lapatinib
lapatinib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- lasmiditan
lasmiditan increases levels of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Comment: Lasmiditan inhibits BCRP in vitro. Avoid coadministration of lasmiditan with BCRP substrates.
- leniolisib
leniolisib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Leniolisib, a BCRP inhibitor, may increase systemic exposure of BCRP substrates
- levoketoconazole
levoketoconazole will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- lonafarnib
lonafarnib will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.
- lopinavir
lopinavir will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- lorlatinib
lorlatinib will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- lumacaftor/ivacaftor
lumacaftor/ivacaftor will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- mitotane
mitotane will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- nafcillin
nafcillin will decrease the level or effect of alpelisib by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- osimertinib
osimertinib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- pantoprazole
pantoprazole will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- pentobarbital
pentobarbital will decrease the level or effect of alpelisib by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- phenobarbital
phenobarbital will decrease the level or effect of alpelisib by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
phenobarbital will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - phenytoin
phenytoin will decrease the level or effect of alpelisib by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
phenytoin will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - ponatinib
ponatinib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- primidone
primidone will decrease the level or effect of alpelisib by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
primidone will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers. - regorafenib
regorafenib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- rifabutin
rifabutin will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- rifampin
rifampin will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- rifapentine
rifapentine will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- rolapitant
rolapitant will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- safinamide
safinamide will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- secobarbital
secobarbital will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- St John's Wort
St John's Wort will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with strong CYP3A4 inducers.
- stiripentol
stiripentol will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- sunitinib
sunitinib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- tacrolimus
tacrolimus will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- tafamidis
tafamidis will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- tafamidis meglumine
tafamidis meglumine will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- vandetanib
vandetanib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- velpatasvir
velpatasvir will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- vemurafenib
vemurafenib will increase the level or effect of alpelisib by Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions.
- voxelotor
voxelotor will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.
Monitor Closely (51)
- armodafinil
armodafinil will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- belzutifan
belzutifan will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information.
- bexarotene
bexarotene will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- bosentan
alpelisib will decrease the level or effect of bosentan by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- brigatinib
brigatinib will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- celecoxib
alpelisib will decrease the level or effect of celecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- cenobamate
cenobamate will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.
- chlorpropamide
alpelisib will decrease the level or effect of chlorpropamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- diclofenac
alpelisib will decrease the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- dronabinol
alpelisib will decrease the level or effect of dronabinol by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- elagolix
elagolix will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.
- encorafenib
encorafenib will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
encorafenib will increase the level or effect of alpelisib by Other (see comment). Modify Therapy/Monitor Closely. Encorafenib (a BCRP inhibitor) may increase the concentration and toxicities of BCRP substrates. Closely monitor for signs and symptoms of increased exposure and consider adjusting the dose of these substrates. - eslicarbazepine acetate
eslicarbazepine acetate will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- etravirine
alpelisib will decrease the level or effect of etravirine by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- fedratinib
fedratinib will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.
- fluoxetine
alpelisib will decrease the level or effect of fluoxetine by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- fluvastatin
alpelisib will decrease the level or effect of fluvastatin by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely.
- fosphenytoin
alpelisib will decrease the level or effect of fosphenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- fostemsavir
fostemsavir will increase the level or effect of alpelisib by Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits BCRP transporters. If possible, avoid coadministration or modify dose of BCRP substrate coadministered with fostemsavir.
- glimepiride
alpelisib will decrease the level or effect of glimepiride by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- glipizide
alpelisib will decrease the level or effect of glipizide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- glyburide
alpelisib will decrease the level or effect of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- imatinib
alpelisib will decrease the level or effect of imatinib by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- istradefylline
istradefylline will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.
- ketamine
alpelisib will decrease the level or effect of ketamine by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- lacosamide
alpelisib will decrease the level or effect of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- lenacapavir
lenacapavir will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.
- lesinurad
alpelisib will decrease the level or effect of lesinurad by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- losartan
alpelisib will decrease the level or effect of losartan by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- mestranol
alpelisib will decrease the level or effect of mestranol by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- miconazole oral
alpelisib will decrease the level or effect of miconazole oral by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- momelotinib
momelotinib increases toxicity of alpelisib by plasma protein binding competition. Modify Therapy/Monitor Closely. Momelotinib (BCRP inhibitor) may increase exposure of BCRP substrates, which may increase the risk of BCRP substrate adverse reactions. Dose adjustment of other BCRP substrates may necessary.
- montelukast
alpelisib will decrease the level or effect of montelukast by pharmacodynamic synergism. Modify Therapy/Monitor Closely.
- nateglinide
alpelisib will decrease the level or effect of nateglinide by pharmacodynamic synergism. Modify Therapy/Monitor Closely.
- ospemifene
alpelisib will decrease the level or effect of ospemifene by pharmacodynamic synergism. Modify Therapy/Monitor Closely.
- oteseconazole
oteseconazole will increase the level or effect of alpelisib by Other (see comment). Modify Therapy/Monitor Closely. Otesezonale, a BCRP inhibitor, may increase the effects and risk of toxicities of BCRP substrates. Use lowest starting dose of BCRP substrate, or consider reducing BCRP substrate dose.
- phenytoin
alpelisib will decrease the level or effect of phenytoin by pharmacodynamic synergism. Modify Therapy/Monitor Closely.
- propofol
alpelisib will decrease the level or effect of propofol by pharmacodynamic synergism. Modify Therapy/Monitor Closely.
- rucaparib
rucaparib will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.
- siponimod
alpelisib will decrease the level or effect of siponimod by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- sulfadiazine
alpelisib will decrease the level or effect of sulfadiazine by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- sulfisoxazole
alpelisib will decrease the level or effect of sulfisoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- tamoxifen
alpelisib will decrease the level or effect of tamoxifen by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- tazemetostat
tazemetostat will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- telotristat ethyl
telotristat ethyl will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- tolbutamide
alpelisib will decrease the level or effect of tolbutamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- torsemide
alpelisib will decrease the level or effect of torsemide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- trimethoprim
alpelisib will decrease the level or effect of trimethoprim by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- voriconazole
alpelisib will decrease the level or effect of voriconazole by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- warfarin
alpelisib will decrease the level or effect of warfarin by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- zafirlukast
alpelisib will decrease the level or effect of zafirlukast by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
Minor (8)
- acetazolamide
acetazolamide will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- amobarbital
amobarbital will decrease the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- anastrozole
anastrozole will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- cyclophosphamide
cyclophosphamide will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- dapsone
alpelisib will decrease the level or effect of dapsone by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- larotrectinib
larotrectinib will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- levoketoconazole
levoketoconazole will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- ribociclib
ribociclib will increase the level or effect of alpelisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
Adverse Effects
>10%
Breast cancer
- Glucose increased (79%)
- Creatinine increased (67%)
- Diarrhea (58%)
- Rash (52%)
- Lymphocyte count decreased (52%)
- GGT increased (52%)
- Nausea (45%)
- ALT increased (44%)
- Fatigue (42%)
- Hemoglobin decreased (42%)
- Lipase increased (42%)
- Glucose increased, grade 3-4 (39%)
- Decreased appetite (36%)
- Stomatitis (30%)
- Vomiting (27%)
- Decreased weight (27%)
- Calcium (corrected) decreased (27%)
- Glucose decreased (26%)
- aPTT prolonged (21%)
- Alopecia (20%)
- Rash, grade 3-4 (20%)
- Mucosal inflammation (19%)
- Pruritus (18%)
- Dry skin (18%)
- Dysgeusia (18%)
- Headache (18%)
- Abdominal pain (17%)
- Peripheral edema (15%)
- Pyrexia (14%)
- Platelet count decreased (14%)
- Potassium decreased (14%)
- Albumin decreased (14%)
- Mucosal dryness (12%)
- Dyspepsia (11%)
- Magnesium decreased (11%)
- GGT increased, grade 3-4 (11%)
PROS (all grades)
- Decreased calcium (60%)
- Decreased phosphate (59%)
- Increased glucose (56%)
- Increased HbA1c (38%)
- Increased creatinine (31%)
- Increased bilirubin (29%)
- Increased potassium (24%)
- Decreased leukocytes (22%)
- Decreased hemoglobin (20%)
- Decreased neutrophils (19%)
- Increased triglycerides (19%)
- Decreased magnesium (18%)
- Increased lymphocytes (17%)
- Increased AST (17%)
- Diarrhea (16%)
- Stomatitis (16%)
- Decreased platelets (14%)
- Increased cholesterol (13%)
- Decreased albumin (13%)
- Hyperglycemia (12%)
- Decreased sodium (12%)
- Decreased potassium (12%)
- Increased GGT (11%)
PROS (Grade 3 or 4)
- Increased glucose (11%)
1-10%
Breast cancer
- Urinary tract infection (10%)
- Lymphocyte count decreased, grade 3-4 (8%)
- Diarrhea, grade 3-4 (7%)
- Lipase increased, grade 3-4 (7%)
- Potassium decreased, grade 3-4 (2.1%)
- Fatigue, grade 3-4 (5%)
- Hemoglobin decreased, grade 3-4 (4.2%)
- Decreased weight, grade 3-4 (3.9%)
- ALT increased, grade 3-4 (3.5%)
- Creatinine increased, grade 3-4 (2.8%)
- Nausea, grade 3-4 (2.5%)
- Stomatitis, grade 3-4 (2.5%)
- Mucosal inflammation, grade 3-4 (2.1%)
- Calcium (corrected) decreased (2.1%)
- Abdominal pain, grade 3-4 (1.4%)
- Platelet count decreased, grade 3-4 (1.1%)
PROS (all grades)
- Increased ALT (10%)
- Eczema (7%)
- Dry skin (7%)
- Alopecia (5%)
- Headache (5%)
- Cellulitis (5%)
PROS (Grade 3 or 4)
- Decreased hemoglobin (6%)
- Decreased phosphate (5%)
- Cellulitis (3.5%)
- Increased bilirubin (2%)
- Decreased sodium (2%)
- Decreased platelets (2%)
<1%
Breast cancer
- Pruritus, grade 3-4 (0.7%)
- Urinary tract infection, grade 3-4 (0.7%)
- Headache, grade 3-4 (0.7%)
- Decreased appetite, grade 3-4 (0.7%)
- Vomiting, grade 3-4 (0.7%)
- aPTT prolonged, grade 3-4 (0.7%)
- Dry skin, grade 3-4 (0.4%)
- Dysgeusia, grade 3-4 (0.4%)
- Mucosal dryness, grade 3-4 (0.4%)
- Glucose decreased, grade 3-4 (0.4%)
- Magnesium decreased, grade 3-4 (0.4%)
Postmarketing Reports
Breast cancer
- Skin and subcutaneous tissue disorders: Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Metabolism and nutrition disorders: Hyperglycemic hyperosmolar nonketotic syndrome (HHNKS)
PROS
- Skin and subcutaneous tissue disorders: Pruritus, rash (including rash maculopapular, rash erythematous, rash papular, and rash pruritic), acne (including dermatitis acneiform)
- Metabolism and nutrition disorders: Decreased appetite
Warnings
Contraindications
Hypersensitivity to alpelisib or any of its components
Cautions
Angioedema reported in postmarketing setting
Severe hypersensitivity reactions (eg, anaphylaxis, anaphylactic shock, angioedema) reported; reactions manifested by symptoms including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia; permanently discontinue if hypersensitivity occurs
Severe pneumonitis, including acute interstitial pneumonitis and interstitial lung disease, reported; consider noninfectious pneumonitis in patients presenting with nonspecific respiratory signs and symptoms (eg, hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic examinations) and in whom infectious, neoplastic, and other causes have been excluded; permanently discontinue in all patients if confirmed; advise patients to immediately report new or worsening respiratory symptoms
Based on findings in animals and its mechanism of action, fetal harm may occur when administered to pregnant women
Diarrhea or Colitis
- Severe diarrhea, including dehydration and acute kidney injury, occurred; based on severity of diarrhea, therapy may require dose interruption, reduction, or discontinuation; advise patients to start antidiarrheal treatment, increase oral fluids, and notify their healthcare provider if diarrhea occurs
- Colitis reported in postmarketing setting
- Monitor for diarrhea and additional symptoms of colitis, such as abdominal pain and mucus or blood in stool; based on severity of diarrhea or colitis, dose interruption, reduction, or discontinuation may be necessary
- For patients with colitis, additional treatment, such as enteric-acting and/or systemic steroids, may be required
Severe cutaneous adverse reactions
- Severe cutaneous reactions, including Stevens-Johnson syndrome (SJS) and erythema multiforme (EM) reported
- Do not initiate with history of SJS, EM, or toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS)
- If signs or symptoms of cutaneous reactions occur, interrupt therapy until etiology of reaction determined
- If SJS, TEN, or EM confirmed, permanently discontinue; do not reintroduce in patients who have experienced previous severe cutaneous reactions during treatment
- If cutaneous reactions not confirmed, therapy may require dose modifications, topical corticosteroids, or oral antihistamine treatment
Severe hyperglycemia
- Closely monitor patients with diabetes
- Based on severity of hyperglycemia, therapy may require dose interruption, reduction, or discontinuation
- In some cases associated with hyperglycemic hyperosmolar non-ketotic syndrome (HHNKS) or ketoacidosis; some fatal cases of ketoacidosis have occurred in the post marketing setting
- Before initiating treatment, test FPG and HbA1c, and optimize blood glucose
- After initiation, monitor fasting glucose more frequently for the first few weeks during treatment in patients with risk factors for hyperglycemia such as obesity (BMI greater than or equal to 30), elevated FPG, HbA1c at the upper limit of normal or above, use of concomitant systemic corticosteroids, or age greater than or equal to 75
- Monitor blood glucose and/or FPG at least qWeek for the first 2 weeks, then at least q4Weeks, and as clinically indicated; monitor HbA1c every 3 months and as clinically indicated
- During treatment with antidiabetic medication, continue monitoring blood glucose or FPG at least once a week for 8 weeks, followed by once q2Weeks and as clinically indicated
- Advise patients of signs and symptoms of hyperglycemia (eg, excessive thirst, urinating more often than usual or higher amount of urine than usual, or increased appetite with weight loss)
Drug interactions overview
- Alpelisib: CYP3A4 and BCRP substrate; CYP2C9 inducer
-
CYP3A4 inducers
- Avoid coadministration
- Strong CYP3A4 inducers may decrease alpelisib concentration and/or activity
-
BCRP inihibitors
- Avoid coadministration; if unable to avoid or use alternant drugs, closely monitor for increased adverse effects of alpelisib
- BCRP inhibitors may increase alpelisib concentration and/or risk of toxicities
-
CYP2C9 substrates
- Closely monitor for potential reduced activity of CYP2C9 substrate
- Coadministration of alpelisib with CYP2C9 substrates (eg, warfarin) may reduce plasma concentration of CYP2C9 substrates
Pregnancy & Lactation
Pregnancy
Based on animal data and mechanism of action, fetal harm may occur when administered to pregnant women
No data available in pregnant women to inform the drug-associated risk
Advise pregnant women and females of reproductive potential of fetal risk
Verify pregnancy status in females of reproductive potential before initiating
Animal data
- In animal reproduction studies, oral administration to pregnant rats and rabbits during organogenesis caused adverse developmental outcomes, including embryofetal mortality (postimplantation loss), reduced fetal weights, and increased incidences of fetal malformations at maternal exposures ≥0.8 times the exposure in humans based on AUC at the recommended dose of 300 mg/day
Contraception
- Females of reproductive potential: Use effective contraception during treatment and for 1 week after the last dose
- Male patients with female partners of reproductive potential: Use condoms and effective contraception during treatment and for 1 week after the last dose
Infertility
- Based on findings from animal studies, fertility in males and females of reproductive potential may be impaired
Lactation
There are no data on the presence of alpelisib in human milk, its effects on milk production, or the breastfed child
Because of potential for serious adverse reactions in the breastfed child, advise lactating women to not breastfeed during treatment and for 1 week after the last dose
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Phosphatidylinositol-3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3K-alpha
Gain-of-function mutations in the gene encoding the catalytic alpha-subunit of PI3K (PIK3CA) lead to activation of PI3K-alpha and Akt-signaling, cellular transformation, and generation of tumors in in vitro and in vivo models
Breast cancer
- Inhibits the phosphorylation of PI3K downstream targets and has shown activity in cell lines possessing a PIK3CA mutation
- PI3K inhibition has been shown to induce an increase in ER transcription in breast cancer cells
- Combination with fulvestrant demonstrates an increase in antitumor activity compared with either treatment alone
PIK3CA-related overgrowth spectrum (PROS)
- Activating mutations in PIK3CA induce a spectrum of overgrowths and malformations comprising a wide group of clinically recognizable disorders commonly known as PROS
-
Spectrum includes
- CLAPO syndrome
- CLOVES syndrome
- Diffuse capillary malformation with overgrowth (DCMO)
- Dysplastic megalencephaly (DMEG)
- Fibroadipose hyperplasia (FAH)/fibroadipose overgrowth (FAO)/hemihyperplasia-multiple lipomatosis syndrome (HHML)
- Fibroadipose vascular anomaly (FAVA)
- Facial infiltrating lipomatosis (FIL)
- Hemimegalencephaly (HMEG)
- Klippel-Trenaunay syndrome (KTS)
- Lipomatosis of nerve (LON)
- Macrodactyly
- Megalencephaly-capillary malformation syndrome (MCAP syndrome)
- Muscular hemihyperplasia (HH)
Absorption
Peak plasma concentration at steady-state: 2480 ng/mL
Peak plasma time: 2-4 hr
AUC: 33,224 ng·hr/mL
Steady-state reached within 3 days
Effects of food following a single dose
- High-fat, high-calorie meal (985 calories with 58.1 grams of fat) increased AUC by 73% and peak plasma concentration by 84%
- Low-fat, low-calorie meal (334 calories with 8.7 grams of fat) increased AUC by 77% and peak plasma concentration by 145%
Distribution
Vd: 114 L
Protein bound: 89%
Metabolism
Primarily metabolized by chemical and enzymatic hydrolysis to form its metabolite, BZG791
Metabolized to a lesser extent by CYP3A4
Elimination
Half-life: 8-9 hr
Clearance: 9.2 L/hr
Excretion
- Feces: 81% (36% unchanged, 32% BZG791)
- Urine: 14% (2% unchanged, 7.1 BZG791)
- CYP3A4-mediated metabolites accounted for 12% of the dose
- Glucuronides accounted for ~15% of the dose
Administration
Oral Administration
Take orally with food
Administer dose at approximately same time each day
Swallow tablet whole (do not chew, crush, or split)
Do not ingest if tablet is broken, cracked, or otherwise not intact
Missed dose
- Missed dose ≤9 hr of scheduled time: Take dose
- Missed dose >9 hr of scheduled time: Skip dose for that day; the next day, take dose at usual time
- If dose is vomited, advise not to take an additional dose on that day; resume dosing schedule the next day at the usual time
Compounding oral suspension
- Place tablets in glass containing 2-4 oz water and let it stand for ~5 minutes
- Make suspension with water only
- Crush tablets with a spoon and stir until an oral suspension obtained
- Administer immediately after preparation
- Discard if not administered within 60 minutes after preparation
- After administration, add ~2-3 tablespoons of water to the same glass, stir with same spoon to resuspend any remaining particles and administer entire contents of the glass
- Repeat if particles remain
Storage
Store at 20-25°C (68-77°F), excursions permitted to 15-30°C (59-86°F)
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Piqray oral - | 250 mg/day (200 mg x1-50 mg x1) tablet | ![]() | |
Piqray oral - | 300 mg/day (150 mg x 2) tablet | ![]() | |
Piqray oral - | 200 mg/day (200 mg x 1) tablet | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.